AGF Management Ltd. Sells 60,774 Shares of Amgen Inc. (NASDAQ:AMGN)

AGF Management Ltd. reduced its stake in Amgen Inc. (NASDAQ:AMGN) by 41.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 86,660 shares of the medical research company’s stock after selling 60,774 shares during the quarter. AGF Management Ltd.’s holdings in Amgen were worth $22,587,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. Unionview LLC boosted its stake in shares of Amgen by 3.8% in the 3rd quarter. Unionview LLC now owns 876 shares of the medical research company’s stock valued at $282,000 after purchasing an additional 32 shares during the last quarter. Semus Wealth Partners LLC increased its holdings in Amgen by 2.3% during the third quarter. Semus Wealth Partners LLC now owns 1,531 shares of the medical research company’s stock worth $493,000 after buying an additional 35 shares during the last quarter. Connable Office Inc. raised its stake in Amgen by 0.5% in the 3rd quarter. Connable Office Inc. now owns 6,972 shares of the medical research company’s stock valued at $2,246,000 after acquiring an additional 37 shares during the period. Blossom Wealth Management boosted its stake in Amgen by 3.5% in the 4th quarter. Blossom Wealth Management now owns 1,090 shares of the medical research company’s stock valued at $284,000 after purchasing an additional 37 shares during the period. Finally, Zullo Investment Group Inc. increased its holdings in shares of Amgen by 2.8% during the fourth quarter. Zullo Investment Group Inc. now owns 1,364 shares of the medical research company’s stock worth $356,000 after purchasing an additional 37 shares during the period. 76.50% of the stock is owned by institutional investors.

Insider Buying and Selling at Amgen

In other Amgen news, EVP Jonathan P. Graham sold 25,045 shares of the business’s stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $293.12, for a total value of $7,341,190.40. Following the completion of the sale, the executive vice president now owns 28,987 shares of the company’s stock, valued at $8,496,669.44. The trade was a 46.35 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Nancy A. Grygiel sold 1,589 shares of the company’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the sale, the senior vice president now owns 7,210 shares of the company’s stock, valued at $2,195,228.70. This trade represents a 18.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 69,341 shares of company stock valued at $20,644,335. Company insiders own 0.69% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on AMGN. William Blair reissued an “outperform” rating on shares of Amgen in a research note on Tuesday, November 12th. Citigroup reissued a “neutral” rating on shares of Amgen in a report on Wednesday, February 5th. StockNews.com cut Amgen from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Johnson Rice set a $294.00 price objective on shares of Amgen in a research report on Wednesday, March 5th. Finally, Wolfe Research started coverage on Amgen in a report on Friday, November 15th. They set a “peer perform” rating for the company. Two analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $314.04.

Amgen Stock Performance

Shares of AMGN opened at $318.89 on Wednesday. The company has a market capitalization of $171.31 billion, a price-to-earnings ratio of 42.24, a PEG ratio of 2.63 and a beta of 0.53. The company’s 50 day simple moving average is $288.66 and its 200 day simple moving average is $299.43. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. On average, sell-side analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be issued a dividend of $2.38 per share. The ex-dividend date is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 2.99%. Amgen’s dividend payout ratio (DPR) is presently 126.09%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.